Home - Summit Therapeutics
Recent Publications Ivonescimab Q4 2024 Earnings Call Great Place To Work Summit Therapeutics is proud to have achieved the Great Place to Work® Certification™! Great Place to Work® is a globally recognized and trusted symbol of excellence and indicates Summit is committed to consistently providing our employees with a positive, supportive, and fulfilling work environment.
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-02 | 22.25 |
| 2025-03 | 28.001 |
| 2025-04 | 31.03 |
| Source | Traffic Share |
|---|---|
| search | 49.39% |
| direct | 42.10% |
| referrals | 5.48% |
| social | 2.24% |
| paid referrals | 0.72% |
| 0.07% |
| Region | Percentage |
|---|---|
| United States | 76.59% |
| CH | 3.98% |
| United Kingdom | 3.88% |
| KR | 3.78% |
| Canada | 3.20% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| summit therapeutics | 1,521 | 15,210 | $1.62 |
| summit therapeutics press release | 52 | 520 | $0.00 |
| summit therapeutics pipeline | 68 | 680 | $0.00 |
| summit therapeutics headquarters | 19 | 190 | $0.00 |
| ivonescimab | 617 | 6,170 | $5.05 |